Connect your agent to akta.pro and build company lists like this across sectors and geos.
Private emerging biopharma companies globally with 2026 funding activity, ranked by total capital raised. The shortlist covers oncology, genetic medicine, biologics, precision therapeutics, AI-driven drug discovery, and microbiome therapies. Data compiled .
| Company | Category | Funding | Products & Services | Expansion Signal | Management |
|---|---|---|---|---|---|
| Rakuten Medical 🇺🇸 San Diego Founded 2010 101-250 employees | Oncology Therapeutics | Funding $847.0M Last raised Undisclosed Apr 2026 · Corporate Round | Develops light-activated cancer therapies that pair antibody-dye conjugates with a laser system to destroy tumor cells, with its lead candidate marketed in Japan. ASP-1929 BioBlade Laser System RM-1995 RM-0256 | Ecosystem Buildout Announced plans to bring its light-activated cancer therapy to the US market. | Minami Maeda President and incoming CEO (effective July 1, 2026) Hiroshi \"Mickey\" Mikitani Executive Chairman of the Board (effective July 1, 2026) Abhijit Bhatia Chief Operating Officer (COO) Carlos Garcia Chief Technology Officer (CTO) and U.S. Divisional Officer |
| Enveda Biosciences 🇺🇸 Boulder Founded 2019 251-500 employees | Drug Discovery & Development (Natural Product-Derived Pharmaceuticals) | Funding $840.9M Last raised $311.0M Sep 2026 · Series E | Discovers small-molecule drug candidates from natural products, primarily plants, using an AI platform that combines mass spectrometry with proprietary data to find new therapies. ENV-294 ENV-308 ENV-6946 | Ecosystem Buildout Partnered with an AI developer to speed drug development, cutting review time for its drug records by 89%. | Viswa Colluru, PhD Founder & CEO August Allen Chief Technology Officer Daniel Wee, PhD Chief eXecution Officer Hannah Gordon, PhD Chief Scientific Officer |
| Earendil Labs 🇺🇸 Middletown Founded 2021 11-50 employees | Biologics Drug Discovery | Funding $787.0M Last raised $787.0M Mar 2026 · Series B | Develops an AI-driven biologics discovery platform combining deep learning, generative protein engineering, structural biology and high-throughput experimental validation to discover and optimize novel antibody therapeutics. HXN-1001 HXN-1011 HXN-1021 HX-16108 | Ecosystem Buildout Signed a research collaboration with a global pharmaceutical company to discover and develop bispecific cancer antibodies. | Zhenping Zhu Co-founder, President & Co-CEO Jian Peng Founder & CEO |
| Tessera Therapeutics 🇺🇸 Somerville Founded 2018 101-250 employees | Gene Therapy / Genetic Medicine | Funding $773.1M Last raised Undisclosed Mar 2026 · Grant | Develops in vivo gene editing therapies using a gene writing platform that makes precise genome changes, including single-base edits and insertions, delivered by lipid nanoparticles. Gene Writing™ Lipid Nanoparticle (LNP) Delivery Platform TSRA-196 In Vivo Sickle Cell Disease (SCD) Program | New Product Line Received FDA Fast Track and Orphan Drug designations for its lead genetic medicine program. | Michael Severino Chief Executive Officer, Board Director Jacob Rubens Co-Founder Noubar Afeyan Founder and CEO of Flagship Pioneering (Tessera Founding Team member) Hari Pujar Chief Operating Officer |
| Mirador Therapeutics 🇺🇸 San Diego Founded 2024 11-50 employees | Precision Medicine | Funding $730.0M Last raised $250.0M Jan 2026 · Series B | Develops first-in-class and best-in-class therapies for immune-mediated inflammatory and fibrotic diseases using a proprietary engine that integrates multi-modal patient data. Mirador360™ Precision Development Engine | New Product Line Licensed in an anti-C5a antibody and an anti-C5aR small molecule for all indications. | Mark C. McKenna Founder, Chairman & CEO Olivier Laurent, Ph.D. Chief Scientific Officer Allison Luo, M.D. Chief Medical Officer William Sandborn, M.D. Chief Strategy Officer |
| NewLimit 🇺🇸 South San Francisco Founded 2022 11-50 employees | Epigenetic Therapeutics | Funding $682.2M Last raised $435.0M Jun 2026 · Series C | Develops epigenetic reprogramming medicines that restore youthful function to aged cells using transcription factor payloads delivered by lipid nanoparticle mRNA, starting with liver disease programs. Metabolism Program Immunology Program Vascular Program | Funding Signal Raised a $435M Series C to take its first aging-reprogramming medicine into human trials in 2027. | Jacob Kimmel Co-founder & CEO Brian Armstrong Co-founder & Board Director Blake Byers Co-founder |
| Chai Discovery 🇺🇸 San Francisco Founded 2024 11-50 employees | AI Drug Discovery | Funding $631.0M Last raised $400.0M Jul 2026 · Series C | Builds generative AI foundation models that predict and reprogram molecular interactions, designing novel antibodies, nanobodies and other biologics for drug discovery partners. Chai-1 Chai-2 Chai-2 mAb Chai-3 | Ecosystem Buildout Expanded its collaboration with a large pharmaceutical company after successful wet-lab validation of its AI models. | Joshua Meier Co-founder and CEO Jack Dent Co-founder and President Matt McPartlon Co-founder Jacques Boitreaud Co-founder |
| Kallyope 🇺🇸 New York Founded 2015 51-100 employees | Biopharmaceutical Therapeutics | Funding $581.2M Last raised $94.0M Oct 2026 · Series Unknown | Discovers and develops therapeutics targeting the gut-brain axis, led by an oral TRPM8 antagonist in Phase 3 development for acute migraine. Elismetrep K-554 Klarity™ Platform Novo Nordisk Obesity Ligand Program | M&A Signal Sold three early-stage obesity programs to a large pharmaceutical company and refocused on late-stage migraine trials. | Jay Galeota President & Chief Executive Officer Thomas Maniatis Co-Founder Charles Zuker Co-Founder Richard Axel Co-Founder |
| LifeMine Therapeutics 🇺🇸 Cambridge Founded 2017 51-100 employees | Drug Discovery & Development | Funding $563.0M Last raised $188.0M Aug 2026 · Series E | Mines fungal genomes with AI, machine learning and synthetic biology to discover genetically encoded precision medicines, with a clinical-stage candidate for organ transplantation. Avatar-Rx Platform LIFE-001 GlaxoSmithKline (GSK) Drug Discovery and Development Alliance | Ecosystem Buildout Formed a clinical advisory board of organ transplantation experts to advance its transplant drug candidate. | Gregory Verdine, Ph.D. Co-Founder, President and CEO Richard Klausner, M.D. Co-Founder and Chairman of the Board WeiQing Zhou, MBA Co-Founder and COO Jennifer Jarrett, MBA Board Member; CEO, Damora Therapeutics |
| Orca Bio 🇺🇸 Menlo Park Founded 2016 251-500 employees | Cell Therapy / Biologics | Funding $542.0M Last raised $250.0M Jan 2026 · Series F | Develops high-precision allogeneic T-cell immunotherapies for blood cancers and autoimmune diseases, manufactured on a proprietary single-cell platform that creates defined cell compositions. Orca-T Orca-Q OrCAR-T | New Product Line Won FDA approval for its first-in-class regulatory T-cell therapy for blood-cancer stem cell transplants. | Nate Fernhoff, PhD Co-founder and Chief Executive Officer Jeroen Bekaert, PhD Co-founder and President Bijan Nejadnik, MD Chief Medical Officer J. Scott McClellan, MD, PhD Chief Development Officer |
| Abcuro 🇺🇸 Newton Founded 2020 11-50 employees | Biopharmaceuticals | Funding $520.2M Last raised $66.0M Aug 2026 · Series D | Develops first-in-class monoclonal antibodies targeting KLRG1 to deplete highly cytotoxic T cells implicated in autoimmune disease and cancer, with a lead candidate in late-stage development. Ulviprubart ABC015 | New Product Line Plans a new, potentially registrational trial of its antibody in less severe inclusion body myositis from Q4 2026. | Alex Martin Chief Executive Officer Steven A. Greenberg, M.D. Co-founder and Chief Scientific Advisor H. Jeffrey Wilkins, M.D. Chief Medical Officer George Eldridge Chief Financial Officer |
| Star Therapeutics 🇺🇸 South San Francisco Founded 2018 11-50 employees | Biopharmaceuticals | Funding $515.0M Last raised $200.0M Oct 2026 · Private Equity Round | Discovers and develops first-in-class antibody therapeutics for rare diseases, led by a Phase 3 monoclonal antibody that targets Protein S in von Willebrand disease. VGA039 ELA026 ELA822 | M&A Signal Agreed to sell its lead-asset subsidiary to Incyte for $1.25B upfront and up to $750M in milestones. | Adam Rosenthal, PhD CEO and Founder Sandip Panicker, PhD CSO and Co-Founder Gary Patou, MD CMO Scott Robertson, MBA CBO and CFO |
| Encoded Therapeutics 🇺🇸 South San Francisco Founded 2014 101-250 employees | Gene therapy for neurological disorders | Funding $514.1M Last raised $275.0M Sep 2026 · Series F | Develops one-time AAV-based precision gene therapies that target the underlying genetic cause of severe neurological disorders, with programs in Dravet and Angelman syndromes. ETX101 ETX301 Angelman Syndrome Program Alzheimer's Disease / Tauopathies Program | Ecosystem Buildout Planned a facility expansion in North Carolina after its latest financing. | Kartik Ramamoorthi, Ph.D. Co-founder, Chief Executive Officer & Board Member Stephanie Tagliatela Co-founder, Chief Scientific Officer & Board Member Sean P. Nolan Board Chairman Salvador Rico, M.D., Ph.D. Chief Medical Officer |
| Vedanta Biosciences 🇺🇸 Cambridge Founded 2013 51-100 employees | Microbiome Therapeutics | Funding $477.0M Last raised $40.0M Aug 2026 · Series Unknown | Develops oral live biotherapeutic products made of rationally designed defined bacterial consortia to treat gastrointestinal diseases, led by an eight-strain commensal consortium. VE303 VE202 VE707 Product Engine | New Product Line Cleared a prespecified interim analysis of its pivotal Phase 3 trial, which will continue as planned. | Bernat Olle, Ph.D. Co-founder, Chief Executive Officer, and Board of Directors Alexander Rudensky Scientific Co-founder Dan Littman Scientific Co-founder Ruslan Medzhitov Co-founder & Chair of Scientific Advisory Board |
| CellCentric 🇬🇧 Cambridge Founded 2004 11-50 employees | Oncology Pharmaceuticals | Funding $475.7M Last raised $220.0M May 2026 · Series D | Develops an oral first-in-class small molecule inhibitor of p300/CBP bromodomains for multiple myeloma and other cancers with a combination regimen in a pivotal trial. Inobrodib | New Product Line Started a pivotal trial pairing its inhibitor with standard therapy in relapsed or refractory multiple myeloma. | Will West Chief Executive Officer and Co-founder Azim Surani Scientific Founder and Co-founder Tomasz Knurowski Chief Medical Officer Debbie Haynes Chief Operating Officer |
A company qualifies when it is a private, operating developer of drugs, biologics or genetic and cell-based medicines, or of the discovery platforms behind them, that is still building its pipeline rather than selling an established commercial portfolio. This covers small molecules, antibodies, gene and cell therapies and AI-driven discovery.
The list separates emerging developers from established pharma groups and subsidiaries, contract manufacturers, diagnostics, isotope suppliers, accelerators and companies that have already listed. Across the 15 companies the largest segment by capital is AI-driven discovery, with $1.98B raised by three companies.
The 15 companies have raised $9.48B in total, and the top three account for $2.47B, or 26.1% of that amount.
Out of scope: public companies (including those that completed or announced a listing before the snapshot), established pharma groups and their subsidiaries, contract manufacturers, diagnostics, isotope suppliers, incubators, and any company whose last funding predates 2026.
Companies are tagged against standard industry codes and against akta.pro's internal taxonomy, so the same set can be rebuilt by code, by segment, or by a combination of both.
NAICS 541714 Research and Development in Biotechnology (except Nanobiotechnology) 325414 Biological Product (except Diagnostic) Manufacturing 325412 Pharmaceutical Preparation Manufacturing SIC 2836 BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) 2834 PHARMACEUTICAL PREPARATIONS 8731 SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH Internal taxonomy HLAA Biotechnology & Biologics HLAI PharmaceuticalsIndustry codes are provided for cross-referencing against public filings and procurement records. akta.pro classification is independent of them, so a company may carry an internal segment without a matching NAICS or SIC registration.